The Implantable Artificial Heart Project
ABIOMED, Inc.
News
Press Conferences
News Releases
Frequently Asked Questions (FAQ)
Images and Diagrams
The AbioCor Replacement Heart
Frequently Asked Questions (FAQ)
Images and Diagrams
The Researchers
Laman A. Gray, Jr., M.D.
Robert D. Dowling, M.D.

News Releases

FOR IMMEDIATE RELEASE
September 27, 2004

FOR MORE INFORMATION:
Andrea tenBroek
Communications Specialist
(978) 646-1419
mediarelations@abiomed.com

Investor Relations Contact:
Edward E. Berger, Ph.D.
Vice President for Policy, Reimbursement and External Relations
(978) 646-1411
ir@abiomed.com

Thirteenth AbioCor® Patient Passes Away

Danvers, Mass., September 27, 2004 -- ABIOMED, Inc. (NASDAQ: ABMD) has been informed by Drs. Laman Gray and Rob Dowling, investigators for the AbioCor® clinical trial at Jewish Hospital/University of Louisville, that the thirteenth AbioCor patient died on September 26 of causes related to device operation.

The patient, 73-year-old Don Graham of New Albany, Indiana, received the AbioCor on May 3, 2004 and was supported for 147 days. The 6th patient to receive an AbioCor at Jewish Hospital, he is survived by his wife Bonnie and other family members.

No further information is available at this time. ABIOMED and Jewish Hospital are investigating the situation and will report when an analysis has been completed.

“Our thoughts and prayers are with Don and his family,” said Michael R. Minogue, President and CEO of ABIOMED.

Candidates for the AbioCor clinical trial must suffer from biventricular heart failure, be ineligible for heart transplantation and not able to be helped by any other available therapy, and have a high probability of dying in less than 30 days.

Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced “AB’-EE-O-MED”) is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED, which currently sells the BVS® 5000 Biventricular Support System and the AB5000™ Circulatory Support System, is the market leader in devices for the temporary support of patients with failing but potentially recoverable hearts. The company’s AbioCor® Implantable Replacement Heart is the subject of an initial clinical trial being conducted under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial.

###


©2004 Jewish Hospital, University of Louisville Health Sciences Center, ABIOMED, Inc.
Jewish Hospital University of Louisville Health Sciences Center